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this CYP isoform, such as fluoxetine, sertraline, paroxetine 
and fluvoxamine, may result in the loss of the AN’s efficacy 
or higher toxicity.  Conclusion: Among the ADs, escitalo-
pram, citalopram, venlafaxine, mirtazapine and milnacipran 
stand out for their weak CYP 450 inhibitory potential and 
their safety profile in those patients. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Psychiatric disorders affect about half of the cancer 
patients  [1] . Adjustment disorder is the most frequent di-
agnosis, followed by major depression, with prevalences 
going from 4 to 35% and from 3 to 36%, respectively, ac-
cording to the diagnostic criteria used, the sample stud-
ied (outpatient, pre- or postsurgical), and the type and 
stage of cancer  [2–4] . 
 Several studies have looked at the impact of depression 
on cancer patients, supporting a significant relationship 
between depression and lower quality of life, increased 
perception of pain, suicidal ideas, wish for hastened 
death, low compliance to treatment and a worse progno-
sis  [5–7] . This evidence was the base of several consensus 
conferences, guidelines, algorithms and reviews, devel-
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 Abstract 
 Background and Objectives: Although there is a growing 
impact of psychiatric and depressive disorders in cancer pa-
tients, literature on the idiosyncrasies of antidepressants 
(ADs) used in those conditions and their interactions with 
antineoplastic agents (ANs) is scarce. Sharing the same bio-
transformation pathways enhances the risk of drug interac-
tion between ADs and ANs, specifically when compounds 
are inducers, inhibitors or substrates of cytochrome P450 
(CYP 450). In cancer patients, such drug interactions may re-
sult in less efficacy of the drug and/or increase of their side 
effects. Therefore, the choice of AD should be cautious (safe 
and effective) and well supported. The main purpose of this 
review was to analyze the individual pharmacokinetic prop-
erties of the most used ADs and ANs in order to summarize 
the risk of possible drug interactions between them, antici-
pating the consequences of their coadministration.  Meth-
ods: The authors reviewed books and PubMed online arti-
cles published in the last 6 years.  Results: Most of the ANs 
are subject to transformation by CYP 450 3A4 and their co-
administration with ADs, that have inhibitory properties of 
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oped with the purpose of promoting and conciliating 
psychopharmacological and psychosocial treatments, 
and highlighting the need of evaluating and treating de-
pression in cancer patients  [2, 8, 9] . 
 In fact, the use of antidepressants (ADs) in cancer pa-
tients has increased in the last 20–25 years  [2, 10] , and is 
recommended in the treatment of severe to moderate ma-
jor depression  [11] . Yet, the evidence does not support the 
supremacy of one AD over the other or a pharmacological 
treatment over a psychosocial one  [11] . Nevertheless, it is 
widely accepted that the choice of the AD must take into 
account individual factors, such as side effects, patient’s 
symptoms and preferences, the previous clinical re-
sponse, and coadministered drugs  [11] . 
 In cancer patients particularly, the choice of a psycho-
tropic drug is a challenge that must target ‘not to harm’. 
In fact, those patients are more vulnerable to drug inter-
actions because of their physical fragilities (poor nutri-
tion, weight loss, other medical conditions, young or ad-
vanced age), multimedication and possible enzyme defi-
cit due to genetic polymorphisms or iatrogenic causes 
 [12] . Therefore, the choice of psychotropic drugs must be 
cautious, minimizing the possible increase in adverse 
side effects and the decrease in the efficacy of drugs which 
are crucial to the treatment of cancer.
 Both ADs and antineoplastic agents (ANs) have nar-
row therapeutic indices and consequently, small var -
i ations in their plasmatic concentrations may result
in subtherapeutic or toxic effects  [13] . ANs and ADs
may interact by pharmacokinetic or pharmacodynamic 
mechanisms which are independent of the pharmacolog-
ic properties responsible for their therapeutic efficacy (i.e. 
mechanism of action and ‘class effect’)  [14] . 
 Although pharmacokinetic drug interactions between 
ADs and ANs may result in changes in absorption, dis-
tribution or elimination of one of them (when subordi-
nated to the effect of the other), those relevant to clinical 
practice are attributed mostly to induction or inhibition 
of cytochrome P450 (CYP 450) occurring in phase I bio-
transformation  [13, 15–17] . In fact, most ANs and ADs 
are metabolized by CYP 450 enzymes, and it is precisely 
this sharing of biotransformation pathways that carries a 
high potential of interaction resulting in an increase or 
decrease in plasmatic concentrations  [13, 15] .
 On the other hand, pharmacodynamic drug interac-
tions occur when the concomitant use of two drugs 
modifies their pharmacological effect and does not 
change their pharmacokinetics (plasmatic concentra-
tion sustained)  [12, 13] . Those reactions may be additive, 
synergic or antagonistic, and are usually predicted ac-
cording to the mechanism of action of each agent on the 
target receptor or enzyme  [14] . In fact, in the last decade, 
in vitro studies have been used to evaluate, understand 
and anticipate the risk of drug interactions  [14] . In spite 
of the recognized limitations, this emerging knowledge 
and evidence is of great value in building a descriptive 
scientific model of the pharmacokinetic and pharmaco-
dynamic behavior of these drugs, allowing to anticipate 
and to prevent potentially adverse drug interactions 
 [14] . 
 In psycho-oncology, except for the research on the si-
multaneous use of ADs and tamoxifen (TMX) in breast 
cancer patients  [18, 19] , the literature is scarce on reviews 
or research addressing the drug interactions between 
ANs and ADs and their clinical consequences. Recently, 
in Singapore, OncoRx has been developed  [13] . It is a 
computer database, still with restricted access, which fa-
cilitates the knowledge of probable drug interactions be-
tween the main groups of ADs and ANs, used as mono-
therapy or chemotherapy protocols, based on known 
pharmacokinetic parameters  [13] . 
 Recognizing the importance of this issue, the authors 
propose to analyze the individual pharmacokinetic pro-
file of the most commonly used ADs and ANs, and point-
ed out possible interactions between these two groups of 
drugs, emphasizing the risk of toxicity from antineoplas-
tic activity. 
 Method 
 In this review, papers published after 2005, namely specific 
books about drug interactions in psychiatry and psychopharma-
cology and online papers were considered. PubMed articles were 
retrieved through the association of the following terms: antide-
pressants, tricyclic antidepressants, depression, anticancer drugs, 
antineoplastic drugs, tamoxifen and oncology; with the words: 
metabolism, CYP 450 inhibition and drug interactions. More-
over, for a specific drug (x) whose biotransformation pathway was 
not clarified by the previous method, an individual research was 
performed in Google (‘x metabolism’). Only two papers aged 12 
and 13 years were chosen because of their value to the realization 
of this review. 
 Metabolism of Drugs: CYP 450 
 Among the 4 major phases which are part of the phar-
macokinetic process –absorption, distribution, metabo-
lization and elimination – biotransformation is the one 
that deserves to be highlighted concerning drug interac-
tions  [14] . In this phase, the following possibilities must 
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be considered: (1) the ‘parent compound’ (pro-drug) 
needs to be metabolized into an active metabolite (Ac-
tiveMet) to have a therapeutic effect; (2) the ‘parent com-
pound’ is active and after metabolization, ActiveMet(s) 
are formed but with different pharmacologic properties 
which are usually responsible for side effects; (3) the ‘par-
ent compound’ is active and deactivated after metabo-
lization  [20] . 
 Drug biotransformation depends on 2 phases: phase I 
(oxidation), which covers redox or hydrolytic reactions 
responsible for the conversion of lipophilic drugs into 
more polar metabolites (e.g. alcohols, phenols and car-
boxylic acids), and phase II reactions of conjugation 
forming products such as glucuronides and sulfates, 
readily excreted in urine  [14] .
 Most phase I reactions are catalyzed by CYP 450 local-
ized mostly in the liver. CYPs are a group of about 30 
oxidative heterogeneous isoenzymes classified in fami-
lies by numbers (CYP 1, CYP 2 and CYP 3) and in sub-
families by a capital letter, based on the shared amino 
acid sequences. In humans, the CYP P450 isoforms most 
involved in the metabolization of drugs are 1A1, 1A2, 
2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 2J2, 3A4, 3A5 and 
3A7  [14] . The CYP 2D6 and CYP 3A4 isoforms are re-
sponsible for metabolizing most psychotropics  [12] and 
they can be subject to induction or inhibition by other 
drugs or substances. 
 The evidence shows that the activity of a pro-drug, 
which is transformed into an ActiveMet, is increased in 
the presence of an inducer, being the contrary true for 
those being inactivated after metabolization. However, 
when a drug interaction changes the concentration of a 
‘parent drug’ and its metabolites, and when both are 
equivalent in efficacy and safety, the inhibition or induc-
tion has little therapeutic implications  [21] .
 Besides coadministered drugs, also the patient’s phys-
iologic status (age, gender, and comorbidity) and his/her 
genetic polymorphisms may be responsible for different 
drug-metabolizing enzyme activity  [21] . It is estimated 
that genetics may explain 20–95% of variability in the 
therapeutic response and toxicity  [21, 22] .
 The Particular Case of TMX 
 Among the ANs, TMX is the one more extensively 
studied for drug interactions with ADs. TMX is a selec-
tive modulator of estrogen receptors  [12] . In women with 
breast cancer and at the initial stage, the use of TMX has 
been associated with a reduced risk of recurrence at about 
1/2 and death risk by breast cancer at about 1/3  [12] . TMX 
is converted to endoxifen, its ActiveMet, by the most 
polymorphic and well-studied gene of the CYP 450 sys-
tem: CYP 2D6  [12] . More than 80 different major alleles 
 were identified, many of which are responsible for in-
creased or reduced activity of CYP 2D6  [15, 23–26] . Thus, 
based on the genotype, individuals can be divided into 
weak, intermediate, extensive or very extensive metabo-
lizers  [15] . The CYP 2D6 lack of activity compromises 
TMX efficacy by reducing its bioactivation to endoxifen 
 [15, 23–26] .
 Several studies have shown that drugs that inhibit 
CYP 2D6 can reduce the clinical benefit of TMX  [27, 28] . 
SSRIs inhibit, to varying degrees, CYP 2D6  [19] ( ta-
ble 1 ). Pharmacological inhibition of CYP 2D6 has also 
been associated with worse breast cancer prognosis. 
This observation is consistent with the critical role of 
CYP 2D6 in the metabolic activation of TMX and puts 
in evidence a drug interaction that can and should be 
avoided.
 Interactions between ADs and Cytostatics 
 Drug interactions can result in clinically significant 
changes in pharmacokinetics and/or pharmacodynamics 
of ANs altering their therapeutic efficacy and toxicity. 
Concerning ANs, at present, the majority of information 
available comes from animal experiments or in vitro tests 
 [21] . Despite these limitations, research has provided 
valuable information on the pharmacokinetics of either 
ADs or ANs, allowing the integration of these data to pre-
dict possible drug interactions between these two catego-
ries of drugs. 
 Recent studies focusing on the inhibitory properties of 
tricyclic ADs are scarce. However, there is some evidence 
on their moderate to high inhibitory potential on CYP 
2C19 and CYP 2D6 isoenzymes  [29, 30] . Much more in-
formation is available about SSRIs. Besides markedly in-
hibiting CYP 2D6, fluoxetine inhibits moderately CYP 
2C19 and 2C9 isoenzymes  [14, 19, 31] . Sertraline can also 
cause moderate inhibition of CYP 2C19  [32] and fluvox-
amine is a strong inhibitor of CYP 1A2, 2C9 and 2C19 
isoenzymes  [14, 31] . As for paroxetine, its inhibitory po-
tential is high for both CYP 2D6 and 2B6  [14, 31] . All 
these drugs also inhibit, to a mild degree, CYP 3A4 iso-
enzyme  [14, 19, 31, 32] . 
 Citalopram, escitalopram, venlafaxine and mirtazap-
ine are among the ADs whose inhibitory potential is 
smaller  [14, 31] . Milnacipran stands out for minimal he-
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patic metabolization (limited to conjugation with gluc-
uronic acid) being its involvement in pharmacokinetic 
intermediate metabolizers  [33–35] unlikely.
 Regarding the potential pharmacokinetic drug inter-
actions between ANs and ADs and particularly regarding 
the risk of toxicity and loss of effectiveness of ANs, the 
combined analysis of the AD pharmacokinetic data and 
the known evidences about AN metabolization ( table 2 ) 
support the following considerations.
 (1) Altretamine and lomustine are subject to extensive 
hepatic metabolization with the generation of ActiveMet 
 [36] . The isoenzymes of CYP 450 involved in the biotrans-
formation of these ANs are still unknown  [36] . However, 
with fluoxetine, fluvoxamine and paroxetine, moderate to 
powerful inhibitors of multiple isoenzymes of CYP 450 
 [14, 31] , the reduced effectiveness of these ANs, when co-
administered with these ADs, is foreseeable.
 (2) The evidence based on animal studies does not sug-
gest that busulfan and chlorambucil are metabolized by 
the system CYP 450  [36] . Regarding estramustine, me-
chlorethamine, melphalan, temozolomide, 5-fluoroura-
cil, gemcitabine, mercaptopurine, thioguanine, cisplatin, 
carboplatin, oxaliplatin, daunorubicin, doxorubicin, epi-
rubicin and vorinostat, to date, there is no evidence of the 
involvement of the system CYP 450 in the metabolization 
of these ANs, suggesting that in these cases drug interac-
tion with ADs is rare  [36] .
 (3) Cyclophosphamide and procarbazine are metabo-
lized by CYP 2B6 to ActiveMets  [36] . The concomitant 
use of an inhibitor of CYP 2B6 (e.g. paroxetine to a great-
er degree and fluoxetine, sertraline, fluvoxamine and bu-
proprion to a lesser degree  [14, 31] ) can reduce the effec-
tiveness of these ANs. In the particular case of cyclophos-
phamide, which is subject to metabolization by CYP 
2C19 generating its ActiveMet, the CYP 2C19 inhibitors 
(e.g. sertraline  [32] , fluoxetine  [14, 31] , fluvoxamine  [14, 
31] and tricyclic ADs  [35] ) can also reduce its effective-
ness. 
 On the other hand, the biotransformation of cyclo-
phosphamide via CYP 3A4 leads to the formation of inac-
tive metabolites. Therefore, by the use of CYP 3A4 in-
hibitors more active drug may be available (increased ef-
ficacy/toxicity ratio) and the coadministration with a 
CYP 3A4 inducer can be translated into higher neurotox-
icity  [36] . Procarbazine is subject, to a lesser extent, to 
metabolization in CYP 1A  [36] with the formation of Ac-
tiveMet; therefore, using this isoenzyme’s inhibitors (e.g. 
fluvoxamine  [14] ) can also reduce the effectiveness of this 
AN  [29] . The same applies to dacarbazine whose route of 
biotransformation matches that of procarbazine  [36] . 
 (4) Ifosfamide, thiotepa, toremifene and sunitinib are 
metabolized by CYP 3A4 in ActiveMet  [36] . The inhibi-
tors of this isoenzyme (i.e. fluoxetine, sertraline, parox-
etine and fluvoxamine, even with slight inhibitory poten-
tial  [14] ) may impair the activation of the ANs compro-
mising its therapeutic effect.
 Docetaxel and paclitaxel are also metabolized by CYP 
3A4. For these ANs, the use of a CYP 3A4 inhibitor may 
increase the plasma concentration of taxanes causing 
increased toxicity (e.g. myelosuppression, constitutional 
symptoms and peripheral neuropathy)  [36] . The same oc-
curs with the other ANs in the antimicrotubules category 
(vinblastine, vincristine, vindesine, vinorelbine), cortico-
steroids, etoposide, irinotecan and sorafenib whose over-
lap use with CYP 3A4 inhibitors can increase toxicity, and 
with CYP 3A4 inducers reduce efficacy  [36] . In the case 
Table 1.  Choice among ADs in patients with a history of breast cancer on therapy with TMX
Antidepressant Inhibition
of CYP 2D6
Advice based on evidence
Venlafaxine minimum The safest choice with TMX
Mirtazapine Direct studies are lacking with TMX
Citalopram, escitalopram slight Secondary choices if previous are not viable options
Duloxetine, sertraline,
fluvoxamine
moderate Only citalopram or sertraline were studied directly with TMX, so the risk of decreasing 
endoxifen must be weighed against the benefits of these ADs
Paroxetine, fluoxetine,
buproprion
strong Avoid to combine with TMX 
A dapted from Desmarais and Looper [19].
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Antineoplastic agents Metabolism Probable drug interaction with INDs or INBs
Alkylating agents
Altretamine Hepatic oxidation ] (ActiveMet)
Busulfan $
Chlorambucil $
Cyclophosphamide CYP 2B6 > 2C19
(ActiveMet); CYP3A4 (ActiveMet) 
IND 2B6 may d ActiveMet; INB 2B6 f D efficacy; IND 3A4 can d 
neurotoxicity, INB 3A4 may provide more active D (d Efficacy/toxicity)
Dacarbazine CYP 1A2 > 2E1
(ActiveMet is a methylated DNA)
INB CYP 1A2 and 2E1 may f ActiveMet
Estramustine  y
Ifosfamide CYP3A4 IND may d D activation and generated more metabolites, with 
neurotoxic potential; CYP 3A4 INB f D activation and its efficacy
Lomustine Extensive hepatic oxidation ] (ActiveMet) Potential interaction with CYP 450 INB (d pro-D, f efficacy and d toxicity)
Mechlorethamine  y
Melphalan  y
Procarbazine CYP 2B6 >1 A (ActiveMet) CYP 2B6 or CYP 1A INB may f D efficacy
Thiotepa CYP 3A4 > 2B6 (ActiveMet) 3A4 IND may d ActiveMet, INB may f D efficacy
Temozolomide  y
Antimetabolites
Capecitabine 5-Fluorouracil Pro-D 
CYP 2C9 INB potential





Methotrexate Hepatic metabolism ]
Thioguanine  y
Antimicrotubules
Docetaxel CYP 3A4 CYP 3A4 INB may d taxanes (myelosuppression and peripheral neutropenia); 
CYP 3A4 IND may f taxanes; 





CYP 2D6 INB potential
Probable d with CYP 3A4 INB






Dexamethasone is a CYP 3A4 IND 
Toxicity risk with CYP 3A4 INB and f efficacy with CYP 3A4 IND 
Hormone agonists/antagonists
Anastrazole ] (CYP 3A4 is possible)
CYP 1A2, 2C8, 2C9 and 3A4 INB potential
Exemestane CYP 3A4 (InactiveMet) May d with CYP 3A4 INB; CYP3A4 IND may f efficacy
Letrozole CYP 2A6 e CYP 3A4 (MetInactivo); 
CYP 2 A6 and 2C19 INB
May d with CYP 3A4 INB; CYP3A4 IND may f efficacy
Tamoxifen CYP 2D6 (ActiveMet) CYP 3A4 INB CYP2D6 INB may f efficacy; CYP 3A4 IND may d risk of side effects
(e.g. hot flushes, nausea, vomiting)







Doxorubicin y (CYP 3A4 is possible) 
Epirubicin y
Etoposide CYP 3A4 > CYP 2E1, 1A2 May d with CYP 3A4 INB (d % myelosuppression, mucositis)
Idarubicin y
Irinotecan CYP 3A4 (ActiveMet) 3A4 INB may d formation of SN-38 (d % myelosuppression)
3A4 IND may d conversion of SN-38 to InactiveMet (f Efficacy)
Mitoxantrone ]
Topotecano ]
Table 2.  Metabolism of ANs categorized by major pharmacological classes
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of exemestane and letrozole, the likely toxicity with the 
use of CYP 3A4 inhibitors is translated into myalgia, con-
stitutional symptoms, peripheral edema and hot flushes 
 [29] . Under these conditions, regarding imatinib, the 
most prominent adverse symptoms are the weight gain, 
nausea, vomiting and neutropenia  [36] . The toxicity of 
dasatinib can also increase with the coadministration of 
CYP 3A4 inhibitors  [36] .
 Conclusion 
 In oncological patients, the AD choice is a swing where 
the profile of side effects and pharmacokinetics should be 
well weighed. Drug interactions between ADs and ANs 
can compromise the effectiveness of ANs and increase 
their toxicity with obvious prognostic implications. The 
information available about the metabolization of ADs 
and ANs with emphasis on the CYP 450 system facilitates 
drug interaction prediction, which could be avoided if 
undesirable. 
 The pharmacokinetic drug interactions with ADs are 
unlikely with busulfan, chlorambucil, estramustine, 
mechlorethamine, melphalan, temozolomide, 5-fluoro-
uracil, gemcitabine, mercaptopurine, thioguanine, cis-
platin, carboplatin, oxaliplatin, daunorubicin, doxorubi-
cin, epirubicin and vorinostat. Among the remaining 
ANs considered here, the risk of loss of efficacy or in-
creased toxicity, when coadministered with certain ADs, 
is a possibility. Venlafaxine, mirtazapine, citalopram and 
escitalopram are small inhibitors of CYP 2D6, therefore 
being a safe choice when using TMX. Most of the other 
ANs subjected to metabolization by CYP 450 3A4 should 
be used with caution concomitantly with inhibitors of 
this isoenzyme such as fluoxetine, sertraline, paroxetine 
and fluvoxamine. Escitalopram, citalopram, venlafaxine, 
mirtazapine and milnacipram are ADs with minimal 
CYP 450 inhibitory potential and are therefore safer in 
these patients.
 Limitations of This Review  
 Regarding drug interactions between ANs and ADs, 
neither pharmacodynamic phenomena nor hepatic con-
jugation reactions have been considered. The results pro-
posed  here are from the integration of evidence known 
about the individual pharmacokinetics of the ADs and 
ANs. These are, however, assumptions that need addi-
tional support. In fact, with the exception of extended 
research on TMX, the literature lacks evidence on the im-
pact of different ADs in plasma concentrations of ANs 
(and its metabolites) and its anticancer efficacy and tox-
icity.
 
Antineoplastic agents Metabolism Probable drug interaction with INDs or INBs
Tyrosine kinase inhibitors and monoclonal antibodies
Bortezomib CYP 3A4, 2C19, 1A2, 2D6 and 2C9 Potential for d or f with CYP 3A4 and 2C19 strong INB or IND 
Dasatinib CYP 3A4
(ActiveMet, with activity similar to dasatinib)
d dasatinib with CYP 3A4 INB (d %)
Erlotinib, gefitinib CYP 3A4 May d with CYP 3A4 INB 
Imatinib CYP 3A4 % When conjugated with CYP 3A4 INB (fluid retention, weight gain, nausea, 
vomiting, neutropenia) 
Sorafenib CYP 3A4 May f efficacy with CYP 3A4 IND 









Mammalian target of 
rapamycin (mTOR) 
inhibitor: temsirolimus
CYP 3A4 (5 ActiveMet)
I nactiveMet = Inactive metabolite; d = increase; f = decrease; ] = exact CYP450 isoenzyme unknown;  $ = animal data suggest no involvement of 
CYP 450; y = involvement of CYP 450 in the metabolism is unlikely; . = quickly converted into ActiveMet (drug interaction potential mediated by CYP 
appears to be minimal); % = toxicity; INB = inhibitor; IND = inductor; D = antineoplastic drug; > = metabolization more extensive than. Adapted from 
Scripture and Figg [21] and Tony and Tseng [36].
Table 2 (continued)
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